Introduction: challenges in breast cancer treatment
===================================================

Breast cancer is the most frequently diagnosed malignancy in women. In 2012, an estimated 229,060 new cases of invasive breast cancer and 39,920 cancer deaths were expected in women in the United States \[[@B1]\]. With the availability of modern diagnostic tools and increased use of adjuvant systemic therapies, significant progress has been made on early stage breast cancer treatment, and consequently the overall survival rates in breast cancer patients. However, only marginal improvements have been achieved in patients with relapsed metastatic cancer, making it an urgent medical need to develop new, effective therapeutics to treat late-stage breast cancer.

Small molecule inhibitors targeting selected protein kinases and monoclonal antibodies targeting cell-surface receptors have shown promising results in the fight against cancer, including breast cancer, in the past decade. However, the success stories have been limited to only a handful of drug targets. Many of the key cancer-causing genes are traditionally considered \'nondruggable\' \[[@B2]\], and thus not enough effort has been dedicated to these genes. Moreover, tumor heterogeneity and genetic instability make it unlikely that a single target will suffice for long-term treatment of most solid tumors.

Ever since its discovery \[[@B3]\], RNA interference has been considered to be capable of rapidly and efficiently knocking down the expression of any gene in any cell type, thus opening a door to treat cancer by targeting every cancer-causing gene. Recent progress in research in gene silencing agents and their delivery systems has shed light on the potential of these therapeutic agents for cancer treatment.

In this review, we will summarize the current status of development of gene silencing agents as breast cancer therapeutics and describe the enabling systems for effective delivery of such therapeutics.

Gene silencing agents in breast cancer
======================================

Introduction
------------

Two classes of gene silencing agents have been the focus of intense study in recent years: small interfering RNA (siRNA) and small non-coding microRNA. The siRNA molecule regulates expression of a specific protein via degradation of the mRNA molecule. It usually demands a perfect match between the siRNA oligo and the corresponding sequence in mRNA (Figure [1](#F1){ref-type="fig"}). On the other hand, microRNA molecules regulate gene expression via suppression of translation. One microRNA molecule often modulates the expression of a group of genes.

![**Schematic view of the mechanisms of action of small interfering RNAs (siRNAs) and microRNAs (miRNAs)**. siRNAs and miRNAs are packaged into nanoparticles for effective delivery. **(A)**Once inside the cell, the anti-sense strand of the siRNA duplex anneals to the corresponding mRNA molecule (inside or outside of the open-reading frame), and triggers mRNA degradation. **(B)**On the other hand, the microRNA targets the 3\'untranslated region of the mRNA, and suppresses protein synthesis.](bcr3413-1){#F1}

Small inhibitory RNA
--------------------

Although originally discovered as long double-stranded RNA molecules, double-stranded siRNA constructs of 30 nucleotides or less have been the default choice to avoid interferon response from longer molecules \[[@B4]\]. Thousands of siRNA-related research articles have since been published that demonstrate the essential roles of the individual genes in cell growth and viability. Key cancer genes have also been identified through screening of siRNA/small hairpin RNA (shRNA) libraries for cell proliferation and survival \[[@B5]\]. These genes are involved in almost all the important signal transduction pathways that control tumor initiation, progression, metastasis, and tumor angiogenesis. Detailed information on the individual genes has been published elsewhere, and is not the scope of this article. It has been estimated that there are about 80 mutations in an individual breast tumor, of which a dozen are driving mutations \[[@B6]\]. Adding to the complexity, every cancer patient carries a unique spectrum of gene mutations, making the pool of mutant genes unimaginably large. While the current small molecule cancer drugs can only impact a very small portion of cancer-causing genes, the availability of the specially designed siRNAs targeting the large number of genes makes it possible for personalized treatment of breast cancer based on the genetic and epigenetic changes of every patient.

Genes and pathways that contribute to resistance to current cancer therapy have also been identified. Trastuzumab has been a key drug to treat Her2-positive breast cancer patients, but not everyone who is positive for Her2 responds to the treatment. In a large scale RNA interference screening with the Her2-overexpressing BT474 breast cancer cell line, Berns and colleagues \[[@B7]\] discovered that loss of PTEN expression caused resistance to trastuzumab treatment. Since PTEN is a negative regulator of the phosphoinositide 3-kinase (PI3K)/AKT pathway, it is speculated that activation of PI3K signaling confers therapy resistance to trastuzumab. To support this notion, it was found that overexpression of PI3K also caused therapy resistance \[[@B7]\]. Another application of siRNA is to sensitize chemotherapy by knocking down expression of multidrug resistant genes in breast cancer cells. Details will be described in the \'Overcoming therapy resistance\' section below.

microRNA
--------

The microRNAs can be arbitrarily divided into two groups based on their target genes in breast cancer. Table [1](#T1){ref-type="table"} lists microRNAs that play significant roles with known target genes in breast cancer. The group I micro-RNAs regulate key genes in cancer cell growth and survival. These include let-7, miR-17/20, miR-21, miR-103/107, the miR-200 family and miR-708, and more members will be identified. One of the first identified microRNAs was let-7. This molecule regulates expression of such important cancer genes as *KRAS*and *MYC*\[[@B8]\]. Another example is miR-21, which is overexpressed in breast cancer. It modulates the activity of PI3K/AKT and ERK1/2 pathways via control of PTEN expression. Consequently, treatment of MDA-MB-231 human breast cancer cells with a miR-21 antagomir reversed the oncogenic phenotype of the cell line \[[@B9]\]. In contrast to those described above, miR-103/107 exert their global control of gene expression through modulating dicer expression \[[@B10]\]. Owing to the pivotal role of Dicer in processing and maturation of all non-coding microRNAs, fluctuation of miR-103/107 levels could have a genome-wide impact on gene expression.

###### 

microRNAs as potential targets for breast cancer therapy

  microRNA         Selected target gene(s)   Function                                                References
  ---------------- ------------------------- ------------------------------------------------------- ------------------
  let-7            *KRAS*, *MYC*             Tumor growth inhibition                                 \[[@B8],[@B47]\]
  miR-17/20        *CCND1*, *IL-8*           Regulation of tumor microenvironment                    \[[@B48]\]
  miR-21           PTEN/AKT pathway          Tumor progression and metastasis                        \[[@B9]\]
  miR-103/107      Dicer                     Global microRNA downregulation                          \[[@B10]\]
  miR-200 family   *ZEB1*, *SIP1*            Epithelial-mesenchymal transition                       \[[@B49]\]
  miR-205          *HER3*, *E2F*, *ZEB1*     Regulation of HER3 expression                           \[[@B11]\]
  miR-206          *ERα*                     Suppression of ERα expression                           \[[@B50]\]
  miR-221/222      *ERα*                     Tamoxifen resistance by suppression of ERα expression   \[[@B51]\]
  miR-708          *NNAT*                    Inhibition of tumor metastasis                          \[[@B52]\]

Molecules such as miR-205, miR-206, and miR-221/222 represent members of the group II microRNA family. Besides regulating expression of many other genes, members in this group also affect the expression of breast cancer surface markers such as HER3 and ERα. For example, miR-205 is one of the regulators of HER3 expression \[[@B11]\]. Interestingly, a recent report revealed that the expression of miR-205 itself was down-regulated by Her2 \[[@B12]\].

It is noteworthy that expression of one specific gene could be controlled by several microRNA molecules. As indicated in Table [1](#T1){ref-type="table"}, both the miR-200 family and miR-205 modulate epithelial-mesenchymal transition through regulating *ZEB1*expression, and ERa expression is regulated by miR206 and miR-221/222.

Systemic delivery of gene silencing agents for breast cancer therapy
====================================================================

Challenges in delivery of therapeutic agents
--------------------------------------------

Most studies on the biological functions of gene silencing agents have so far been performed using cell-based assays. The excitement and effort in this research field have not been successfully translated into Food and Drug Administration-approved drugs for treatment of human cancers. The fundamental problem with *in vivo*application of gene silencing agents is the lack of effective carriers for systemic delivery in order to overcome the multiple biological barriers \[[@B13]\]. Once inside the circulation, the therapeutic agent needs to survive attack from plasma ribonucleases. Without effective protection, most double-stranded RNA oligos will be digested within minutes. They will also need to escape elimination by the reticulo-endothelial system (the sinusoids of the liver, the spleen, and the alveolar beds of the lung). Upon reaching the tumor vasculature, the agents will have to fight against the unfavorable tumor interstitial pressure in order to cross the blood vessel wall. Once inside the tumor tissue, they still need to cross the extracellular matrix and bypass the connective tissues before reaching tumor cells. Since the unmodified double-stranded RNA oligos are negatively charged, they cannot pass the cytoplasmic membrane to reach the cytosol where they act. The default choice to facilitate cell entry of siRNA or microRNA is to package them into cationic nanoparticles. Nanotechnology has played a predominant role in the design of various forms of carriers for *in vivo*delivery of gene silencing agents so far.

Nanotechnology in breast cancer therapy
---------------------------------------

Interestingly, nanotechnology has been used in breast cancer therapy for decades. Doxil, the liposomal formulation of doxorubicin, is the first nano-drug approved for breast cancer therapy; doxorubicin is a potent anticancer drug for breast cancer treatment. However, it tends to accumulate in the heart, thus causing severe cardiac side effects. Nano-formulation of doxorubicin dramatically reduced cardiac side effects \[[@B14]\] while preserving or even enhancing the therapeutic effect of the active drug \[[@B15]\]. Abraxane, the nanoparticle albumin-bound paclitaxel, is another success story of nanotechnology in breast cancer therapy. Paclitaxel has been widely used to treat multiple cancer types, including breast cancer. Traditionally, paclitaxel has been formulated in Cremophor^®^EL since the active drug is hydrophobic. However, this solvent itself can cause severe side effects, such as allergic reactions and neutropenia. Packaging of paclitaxel into the 1303nm albumin-bound formulation allows for a 50% increase in drug dosage as a result of decreased overall toxicity compared to the solvent-based formulation \[[@B16]\].

Nanotechnology-based delivery systems for gene silencing agents
---------------------------------------------------------------

Multiple technology platforms have been developed to deliver gene silencing agents for cancer therapy. The most common approach is to package the double-stranded RNA into nanoparticles that are less than 2003 nm in diameter. This approach takes advantage of the enhanced permeability and retention effect of the leaky tumor vasculature \[[@B17]\]. Since the tumor blood vessel endothelium is disorganized with gaps ranging from 100 to 5003 nm at the cell juncture \[[@B18]\], the nanoparticles can easily cross the fenestration to reach tumor interstitium (Figure [2](#F2){ref-type="fig"}). Based on the nature of the packaging material, this group of delivery carriers can be divided into lipid-based and non-lipid-based nanovectors. The lipid-based nanovectors include liposomes \[[@B19]\], stable nucleic acid lipid particles (SNALPs) \[[@B20]\], and lipidoid nanoparticles \[[@B21]\]. Non-lipid-based nanovectors contain chitosan \[[@B22]\], poly(amido amine) dendrimers \[[@B23]\], polyethylenimines \[[@B24]\], or other polymeric materials as the building blocks. Conjugates composed of lipid-polymers or polymer-polymers have also been frequently used for siRNA delivery \[[@B25]\]. Another commonly used siRNA carrier is gold nanoparticles. In addition, nanoparticles free of any added materials except the siRNA building block itself have also been reported \[[@B26]\]. Dependent on whether there are targeting moieties on the surface of the particles, these delivery carriers can also be divided into active targeting and passive targeting vectors (Figure [2](#F2){ref-type="fig"}). A few products that are currently in clinical trial are introduced below.

![**Schematic views of nanoparticle delivery**. **(A)**Nanoparticle delivery by passive targeting. In this mode, nanoparticles pass through the leaky vasculature and enter tumor tissues. **(B)**Nanoparticle delivery by active targeting. In this mode, the surface of nanoparticles is coated/conjugated with an active targeting moiety, such as peptide, antibody, or aptamer. Binding of the targeting moiety with cell surface molecules facilities tumor tissue entry of the nanoparticle.](bcr3413-2){#F2}

### RNA delivery by passive targeting

siRNA oligos have taken the lead to reach clinical trials for cancer therapy. Most of the current candidate drugs are formulated into lipid-based nanovectors without active targeting moieties on the surface. Both TKM-PLK-1 from Tekmira Pharmaceuticals and ALN-VSP02 from Alnylam Pharmaceuticals use SNALPs as the delivery vector. The SNALPs consist of the ionizable cationic lipid 1,2-dilinoleyloxy-3-dimethylaminopropane (DLinDMA) as the core lipid component. They have a high siRNA encapsulation capacity with a small and uniform size. TKM-PLK-1 consists of a polo-like kinase31 (PLK1)-specific siRNA packaged in SNALPs. PLK1 is involved in cell cycle progression, and targeted delivery of PLK1 siRNA suppresses growth and metastasis of Her2+ breast cancer in orthotopic xenograft models \[[@B27]\]. ALN-VSP2 is the first product with dual targeting agents, consisting of siRNA oligos specific to the vascular endothelial growth factor (VEGF) and kinesin spindle protein (KSP) \[[@B28]\]. It is hypothesized that knocking down both genes in the same cancer cells might have an additive or even synergistic effect on cell growth and viability. New cationic lipid molecules have recently been identified to prepare more effective SNALP for siRNA delivery \[[@B29]\]. It is anticipated that more gene silencing products based on SNALP will be developed in the coming years. Since SNALP tends to accumulate in the liver, the main indication of these drugs is to treat liver cancer or liver metastasis of other solid cancers.

Atu027 from Silence Therapeutics is composed of a protein kinase N3 (*PKN3*)-specific siRNA in positively charged liposomes prepared with a mixture of cationic and fusogenic lipids \[[@B30]\]. PKN3 is a downstream effector of the PI3K pathway, one of the most important pathways in breast cancer biology. Knockdown of PKN3 impairs growth of primary breast and prostate tumor, and blocks tumor metastasis \[[@B31]\]. A phase I trial with advanced solid cancer has been completed with this agent \[[@B32]\].

siRNA-EphA2-DOPC is formulated by mixing the *EphA2*siRNA with the neutral lipid 1,2-dioleoyl-*sn*-glycero-3-phosphocholine in an excessive amount of *t*-butanol followed by lyophilization \[[@B33]\]. *EphA2*encodes the ephrin receptor tyrosine kinase that is overexpressed in multiple cancer types, including breast cancer. Blocking EphA2 activity by antibody-drug conjugates or through knockdown of gene expression inhibits tumor growth \[[@B33]\]. Additionally, dual targeting of *EphA2*and other cancer genes has shown enhanced tumor growth inhibition \[[@B34]\]. Although most of the initial studies have been focused on ovarian cancer, the disease indication for the current clinical trial includes all solid tumors \[[@B35]\].

### RNA delivery by active targeting

CALAA-01 from Calando Pharmaceutics is not only the first siRNA therapeutic in a human cancer clinical trial but is also formulated with active targeting \[[@B36]\]. The siRNA specific for the M2 subunit of ribonucleotide reductase (RRM2) is encapsulated in a cyclodextrin nanoparticle. An affinity moiety of the human transferrin protein targeting ligand is decorated on the surface of the nanoparticle. It has been well documented that the transferring receptor protein is overexpressed on the surface of cancer cells, and can be used for effective tumor targeting \[[@B37]\]. The 70nm nanoparticles are small enough to cross the fenestration following systemic administration. Once inside the tumor tissue, the targeting moiety would direct the nanoparticle to tumor cells with overexpressed transferring receptor. The first-in-human cancer trial has demonstrated accumulation of RRM2. siRNA in tumor tissues and gene-specific knockdown of expression \[[@B36]\]. Although the clinical trial was carried out with melanoma patients, there is no reason to believe that CALAA-01 cannot be used to treat other cancer types such as breast cancer given that RRM2 controls DNA synthesis and damage repair during the cell cycle.

### Multistage vector for RNA delivery

The multistage vector (MSV) delivery system was designed to maximize tumor delivery of therapeutic agents through sequential negotiation with the biological barriers \[[@B13]\]. The system consists of a first stage nanoporous silicon microparticle and a second stage nanoparticle loaded into the nanopores of the first stage particle. For delivery of gene silencing agents, the double-stranded RNA molecules are packaged into 30 to 40 nm liposomes that are then loaded into the 60 to 80 nm pores of the porous silicon \[[@B38],[@B39]\]. Once inside the bloodstream, the first stage particles travel with the blood flow and settle at tumor vasculature, where the liposomal siRNAs are released. The pace of siRNA release is determined by the diameter of the nanopore, the size of the liposome, and the rate of silicon degradation.

The first stage microparticles are designed based on size, shape, and surface chemical properties to achieve maximal tumor enrichment. The hemispherical and discoidal particles are more effective in adhesion to tumor vasculature than particles with other shapes such as spherical and cylindrical \[[@B40]\]. The size of the micro-particle is a major determinant of particle accumulation. The 1 µm discoidal particles accumulate more than the sub-micrometer or the 3.2 µm particles with the same shape in melanoma tissues \[[@B40]\]. Interestingly, the size of the particle also affects the efficiency of affinity targeting. Surface conjugation of the RDG targeting moiety significantly enhances tumor accumulation of the sub-micrometer particles, but has minimum impact once the size exceeds 1 µm \[[@B40]\]. Surface chemical modification not only affects protein binding but also determines the loading efficiency of the second stage particles into the nanopores. Since the liposomal siRNA carries a negative Zeta potential, the surface of the nanopores is modified with polyamine to facilitate loading of nanoparticles \[[@B41]\].

This system has been successfully applied to deliver siRNA for cancer treatment with experimental tumor models \[[@B38],[@B39],[@B42]\]. Treatment of tumor mice with one dose of MSV/EphA2 siRNA resulted in knockdown of *EphA2*expression for up to 3 weeks due to sustained release of liposomal siRNA \[[@B39]\]. It is suspected that the MSV/siRNA in tumor vasculature and other organs serves as a depot for constant supply of the gene-silencing agent \[[@B43]\]. In a recent study, Xu and colleagues \[[@B42]\] treated an orthotopic model of MDA-MB-231 primary tumor with siRNA targeting the *ATM*gene delivered in the MSV. Effective knockdown of *ATM*expression resulted in dramatic inhibition of tumor growth. Since efficacy and toxicity constitute the two major aspects of siRNA therapeutics, they also carried out studies to systematically evaluate toxicity that might have been caused by MSV/ATM. After careful evaluation, it was determined that no acute immunotoxicity or sub-acute toxicity was associated with MSV/ATM siRNA, paving the pathway for development of MSV/ATM siRNA as a therapeutic agent for breast cancer \[[@B42]\].

Overcoming therapy resistance
-----------------------------

One area of siRNA therapeutics that has shown great promise is sensitization to chemotherapy. Overexpression of multidrug-resistant genes has been attributed to chemoresistance. MacDiarmid and colleagues \[[@B44]\] used a short hairpin RNA to knock down expression of the *MDR1*gene *in vivo*, and subsequently treated murine models of human cancers with chemotherapy drugs. Navarro and colleagues \[[@B25]\] synthesized a DOPE-PEI (dioleoylphosphatidylethanolamine-polyethylenimine) conjugate to enhance transfection capacity of the low molecular weight PEI. They used the conjugate to deliver *MDR1*-specific siRNA, and demonstrated sensitization to doxorubicin treatment of the otherwise resistant MCF-7 cells. We have recently demonstrated sensitization of docetaxel treatment by *EphA2*siRNA in a murine model of human ovarian cancer \[[@B38]\].

Another area that has gained increasing attention in breast cancer therapy is the target of cancer stem cells. These cells are resistant to conventional chemotherapy, and are the lethal seeds for tumor recurrence and local and distant metastasis \[[@B45]\]. By comparing differential expression between the bulk of cancer cells and cancer stem cells, we have identified a group of candidate genes that might be essential for growth and survival of cancer stem cells \[[@B46]\]. Our recent experience with MSV delivery of cancer stem cell gene-specific siRNA oligos has resulted in the development of new breast cancer therapeutics. These agents are expected to play a significant role in the fight against breast cancer.

Conclusion and perspectives
===========================

Gene silencing agents will continue to contribute significantly to breast oncology treatment. Recent advances in RNA interference have resulted in the development of multiple candidate siRNA therapeutics being evaluated in the clinic. Non-coding microRNAs will follow suit to be added to the candidate drug list soon. On the other hand, development of delivery vectors for most solid tumor types has lagged. There are not many options available to deliver siRNA/microRNA to primary breast cancer. It is ever harder to deliver therapeutics to distant organs of breast cancer metastasis, such as the brain and bone. More effort should be spent on the design and development of tissue-specific and tumor type-specific delivery systems for siRNAs and microRNAs.
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